Switch theme
Sign up to access all valuation multiples
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
2008
8
Last FY Revenue n/a
LTM EBITDA -$30.4M
$23.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Annovis Bio has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$30.4M.
In the most recent fiscal year, Annovis Bio achieved revenue of n/a and an EBITDA of -$26.7M.
Annovis Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Annovis Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$30.4M | XXX | -$26.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$31.3M | XXX | -$26.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$29.8M | XXX | -$24.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Annovis Bio's stock price is $2.
Annovis Bio has current market cap of $45.8M, and EV of $23.6M.
See Annovis Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23.6M | $45.8M | XXX | XXX | XXX | XXX | $-2.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Annovis Bio has market cap of $45.8M and EV of $23.6M.
Annovis Bio's trades at n/a EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Annovis Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Annovis Bio has a P/E ratio of -1.5x.
See valuation multiples for Annovis Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45.8M | XXX | $45.8M | XXX | XXX | XXX |
| EV (current) | $23.6M | XXX | $23.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | -0.9x | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnnovis Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.3M for the same period.
Annovis Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Annovis Bio's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Annovis Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 49% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Annovis Bio acquired XXX companies to date.
Last acquisition by Annovis Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Annovis Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Annovis Bio founded? | Annovis Bio was founded in 2008. |
| Where is Annovis Bio headquartered? | Annovis Bio is headquartered in United States of America. |
| How many employees does Annovis Bio have? | As of today, Annovis Bio has 8 employees. |
| Who is the CEO of Annovis Bio? | Annovis Bio's CEO is Dr. Maria Maccecchini, PhD. |
| Is Annovis Bio publicy listed? | Yes, Annovis Bio is a public company listed on NYS. |
| What is the stock symbol of Annovis Bio? | Annovis Bio trades under ANVS ticker. |
| When did Annovis Bio go public? | Annovis Bio went public in 2020. |
| Who are competitors of Annovis Bio? | Similar companies to Annovis Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Annovis Bio? | Annovis Bio's current market cap is $45.8M |
| Is Annovis Bio profitable? | Yes, Annovis Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Annovis Bio? | Annovis Bio's last 12 months EBITDA is -$30.4M. |
| What is the current EV/EBITDA multiple of Annovis Bio? | Current EBITDA multiple of Annovis Bio is -0.8x. |
| What is the current FCF of Annovis Bio? | Annovis Bio's last 12 months FCF is -$26.0M. |
| What is the current EV/FCF multiple of Annovis Bio? | Current FCF multiple of Annovis Bio is -0.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
